2025 Q4 -tulosraportti
Äänite tulossa
Tänään
0,04 EUR/osake
Viimeisin osinko
0,18%Tuotto/v
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 23.4. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
Vuosittainen yhtiökokous 2025 5.6.2025 | ||
2025 Q2 -tulosraportti 2.6.2025 | ||
2025 Q1 -tulosraportti 11.4.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16.4. · MuokattuGerresheimer: Broad support from creditors Share this news Creditors agree to extend the deadline for the submission of the audited annual and consolidated financial statements for 2025 Sales process for Centor Inc. initiated as planned to optimize the capital and financing structure Düsseldorf, April 15, 2026. Gerresheimer, an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries, has received broad support from its creditors. To date, 96 % of the total volume of 870 million euros in promissory notes have already accepted an extension of the deadline to September 30, 2026, for the submission of the audited annual and consolidated financial statements for the fiscal year 2025. Gerresheimer was able to reach an agreement with its banking partners on an extension that, subject to the fulfillment of customary conditions, also runs until September 30, 2026. In addition, important credit conditions regarding the debt ratio have been waived up to and including the third quarter of the fiscal year 2026. The sales process initiated for the US subsidiary Centor Inc. to optimize the capital and financing structure has started as planned with a double-digit number of interested parties. Gerresheimer expects the transaction to be completed by the end of this year. "We are very pleased with the broad support from our creditors. This will allow us to continue to transparently review the business transactions identified during our investigations and to finalize our annual and consolidated financial statements for 2025," explains Wolf Lehmann, CFO of Gerresheimer AG. "With the sale of Centor, we also have a clear strategy to significantly improve our capital structure by the end of this year." The ongoing investigations initiated by the company into business transactions in the fiscal years 2024 and 2025 necessitated a postponement of the publication of the annual financial statements and consolidated financial statements for 2025, as well as the quarterly financial statements for the first quarter of 2026. Gerresheimer's goal remains to publish the audited annual financial statements and consolidated financial statements for 2025 in June 2026. The publication of the quarterly financial statements for the first quarter of 2026 will follow shortly thereafter. The specific dates for the publication of the annual financial statements and consolidated financial statements for 2025, the quarterly financial statements for the first quarter of 2026, and the Annual General Meeting in 2026 will be announced as soon as possible. Business results so far in the fiscal year 2026 have been in line with expectations. The order level is solid. About Gerresheimer Gerresheimer is an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries. The Group offers a comprehensive portfolio of drug containment solutions, including closures and accessories, as well as drug delivery systems, medical devices, and solutions for the healthcare sector. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices, and digital solutions for therapy support. Gerresheimer ensures safe delivery and reliable administration of medicines to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and meets the growing demand for improved sustainability. With 39 production sites in Europe, America, and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenue of around 2.4 billion EUR in 2024 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Short fallen to 13,03 ( 79 MILL Euro )
·23.3.Approx. 50% of the owners in Gerresheimer are institutions/funds including OLJEFONDET with just under 4%. Second largest shareholder Luxembourg-based Active Ownership bought up significantly during last year. Now owns 8,5-9,0% and I guess they at least have an average purchase price of over 50,- euro per share. The analysts following SILGAN are currently positive on the company. 1-year forecast of 49-61 USD. No growth, but OK P/E - EPS, P/B and purchase will also provide good growth. Offer from SILGAN with settlement in shares and an exchange ratio of 40-50 euro per GXI share is interesting. Exciting times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
0,04 EUR/osake
Viimeisin osinko
0,18%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.4. · MuokattuGerresheimer: Broad support from creditors Share this news Creditors agree to extend the deadline for the submission of the audited annual and consolidated financial statements for 2025 Sales process for Centor Inc. initiated as planned to optimize the capital and financing structure Düsseldorf, April 15, 2026. Gerresheimer, an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries, has received broad support from its creditors. To date, 96 % of the total volume of 870 million euros in promissory notes have already accepted an extension of the deadline to September 30, 2026, for the submission of the audited annual and consolidated financial statements for the fiscal year 2025. Gerresheimer was able to reach an agreement with its banking partners on an extension that, subject to the fulfillment of customary conditions, also runs until September 30, 2026. In addition, important credit conditions regarding the debt ratio have been waived up to and including the third quarter of the fiscal year 2026. The sales process initiated for the US subsidiary Centor Inc. to optimize the capital and financing structure has started as planned with a double-digit number of interested parties. Gerresheimer expects the transaction to be completed by the end of this year. "We are very pleased with the broad support from our creditors. This will allow us to continue to transparently review the business transactions identified during our investigations and to finalize our annual and consolidated financial statements for 2025," explains Wolf Lehmann, CFO of Gerresheimer AG. "With the sale of Centor, we also have a clear strategy to significantly improve our capital structure by the end of this year." The ongoing investigations initiated by the company into business transactions in the fiscal years 2024 and 2025 necessitated a postponement of the publication of the annual financial statements and consolidated financial statements for 2025, as well as the quarterly financial statements for the first quarter of 2026. Gerresheimer's goal remains to publish the audited annual financial statements and consolidated financial statements for 2025 in June 2026. The publication of the quarterly financial statements for the first quarter of 2026 will follow shortly thereafter. The specific dates for the publication of the annual financial statements and consolidated financial statements for 2025, the quarterly financial statements for the first quarter of 2026, and the Annual General Meeting in 2026 will be announced as soon as possible. Business results so far in the fiscal year 2026 have been in line with expectations. The order level is solid. About Gerresheimer Gerresheimer is an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries. The Group offers a comprehensive portfolio of drug containment solutions, including closures and accessories, as well as drug delivery systems, medical devices, and solutions for the healthcare sector. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices, and digital solutions for therapy support. Gerresheimer ensures safe delivery and reliable administration of medicines to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and meets the growing demand for improved sustainability. With 39 production sites in Europe, America, and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenue of around 2.4 billion EUR in 2024 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Short fallen to 13,03 ( 79 MILL Euro )
- ·23.3.Approx. 50% of the owners in Gerresheimer are institutions/funds including OLJEFONDET with just under 4%. Second largest shareholder Luxembourg-based Active Ownership bought up significantly during last year. Now owns 8,5-9,0% and I guess they at least have an average purchase price of over 50,- euro per share. The analysts following SILGAN are currently positive on the company. 1-year forecast of 49-61 USD. No growth, but OK P/E - EPS, P/B and purchase will also provide good growth. Offer from SILGAN with settlement in shares and an exchange ratio of 40-50 euro per GXI share is interesting. Exciting times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 23.4. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
Vuosittainen yhtiökokous 2025 5.6.2025 | ||
2025 Q2 -tulosraportti 2.6.2025 | ||
2025 Q1 -tulosraportti 11.4.2025 |
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 23.4. | ||
2025 Q3 -tulosraportti 9.10.2025 | ||
Vuosittainen yhtiökokous 2025 5.6.2025 | ||
2025 Q2 -tulosraportti 2.6.2025 | ||
2025 Q1 -tulosraportti 11.4.2025 |
0,04 EUR/osake
Viimeisin osinko
0,18%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16.4. · MuokattuGerresheimer: Broad support from creditors Share this news Creditors agree to extend the deadline for the submission of the audited annual and consolidated financial statements for 2025 Sales process for Centor Inc. initiated as planned to optimize the capital and financing structure Düsseldorf, April 15, 2026. Gerresheimer, an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries, has received broad support from its creditors. To date, 96 % of the total volume of 870 million euros in promissory notes have already accepted an extension of the deadline to September 30, 2026, for the submission of the audited annual and consolidated financial statements for the fiscal year 2025. Gerresheimer was able to reach an agreement with its banking partners on an extension that, subject to the fulfillment of customary conditions, also runs until September 30, 2026. In addition, important credit conditions regarding the debt ratio have been waived up to and including the third quarter of the fiscal year 2026. The sales process initiated for the US subsidiary Centor Inc. to optimize the capital and financing structure has started as planned with a double-digit number of interested parties. Gerresheimer expects the transaction to be completed by the end of this year. "We are very pleased with the broad support from our creditors. This will allow us to continue to transparently review the business transactions identified during our investigations and to finalize our annual and consolidated financial statements for 2025," explains Wolf Lehmann, CFO of Gerresheimer AG. "With the sale of Centor, we also have a clear strategy to significantly improve our capital structure by the end of this year." The ongoing investigations initiated by the company into business transactions in the fiscal years 2024 and 2025 necessitated a postponement of the publication of the annual financial statements and consolidated financial statements for 2025, as well as the quarterly financial statements for the first quarter of 2026. Gerresheimer's goal remains to publish the audited annual financial statements and consolidated financial statements for 2025 in June 2026. The publication of the quarterly financial statements for the first quarter of 2026 will follow shortly thereafter. The specific dates for the publication of the annual financial statements and consolidated financial statements for 2025, the quarterly financial statements for the first quarter of 2026, and the Annual General Meeting in 2026 will be announced as soon as possible. Business results so far in the fiscal year 2026 have been in line with expectations. The order level is solid. About Gerresheimer Gerresheimer is an innovative system and solution provider and a global partner for the pharmaceutical, biotech, and cosmetics industries. The Group offers a comprehensive portfolio of drug containment solutions, including closures and accessories, as well as drug delivery systems, medical devices, and solutions for the healthcare sector. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices, and digital solutions for therapy support. Gerresheimer ensures safe delivery and reliable administration of medicines to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and meets the growing demand for improved sustainability. With 39 production sites in Europe, America, and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenue of around 2.4 billion EUR in 2024 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com Short fallen to 13,03 ( 79 MILL Euro )
- ·23.3.Approx. 50% of the owners in Gerresheimer are institutions/funds including OLJEFONDET with just under 4%. Second largest shareholder Luxembourg-based Active Ownership bought up significantly during last year. Now owns 8,5-9,0% and I guess they at least have an average purchase price of over 50,- euro per share. The analysts following SILGAN are currently positive on the company. 1-year forecast of 49-61 USD. No growth, but OK P/E - EPS, P/B and purchase will also provide good growth. Offer from SILGAN with settlement in shares and an exchange ratio of 40-50 euro per GXI share is interesting. Exciting times.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt